Results 181 to 190 of about 1,580,994 (358)

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

Molecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li, Zhijie Cao, Haiyan Xing, Zhenya Xue, Wenbing Liu, Jiayuan Chen, Yihan Mei, Runxia Gu, Hui Wei, Shaowei Qiu, Min Wang, Qing Rao, Jianxiang Wang   +12 more
wiley   +1 more source

Oncology education and the preclinical medical student

, 1974
Thomas J. Ervin
openalex   +1 more source

Fellowship in medical oncology [PDF]

, 1977
Irwin H. Krakoff
openalex   +1 more source

Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting. [PDF]

Cardiooncology
Huang L, Manthena P, Su M, Chandra A, Sadeghi N.   +4 more
europepmc   +1 more source

“…oncology nursing”

, 1976
ANNA HASSELS
openalex   +1 more source

Advances in the applications of monoclonal antibodies in clinical oncology. London, 28-30 May 1986 [PDF]

, 1986
Mike Clark, Richard J. Benjamin, C Bindon, Molly E. Bruggeman, Stephen Cobbold, Lisa K. Gilliland, G Hale, Suofu Qin, Helen Tighe, Herman Waldmann, Horace Sir, William G. Dunn, Mark Bodmer, Jefferson Foote, P. Simon Jones, P R Dear, Karol Sikora, Gérard I. Evan, Stephen Chan, Jonathan Stewart, James Watson   +20 more
openalex   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Retraction: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma

Pathology and Oncology Research
Pathology and Oncology Research Editorial Office
doaj   +1 more source

Correction: Management and outcome of children with high‑risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease. [PDF]

Clin Transl Oncol
de Las Heras BM, Rubio-Aparicio PM, Rubio-San-Simón A, Moreno L, Mazorra P, Almaraz RL, López ML, Guill JB, Segura V, Bermúdez M, Jiménez I, Ramal D, Cañete A.   +12 more
europepmc   +1 more source